# A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

> **NCT05412030** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 388 (actual)

## Conditions studied

- Pneumonia, Bacterial
- Pneumococcal Infections
- Pneumonia, Pneumococcal

## Interventions

- **BIOLOGICAL:** AFX3772
- **BIOLOGICAL:** Prevnar 13
- **BIOLOGICAL:** Prevnar 20

## Key facts

- **NCT ID:** NCT05412030
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-16
- **Primary completion:** 2025-09-18
- **Final completion:** 2025-09-18
- **Target enrollment:** 388 (ACTUAL)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05412030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05412030, "A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05412030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*